Indivior Pharmaceuticals Inc. reported first‑quarter 2026 results that surpassed expectations, with total net revenue of $317 million, a 19% year‑over‑year increase, and adjusted EBITDA of $164 million, up 112% from $78 million in Q1 2025. Net revenue from the flagship product SUBLOCADE rose 32% to $232 million, driven by a record 31,800 new patient starts and a 33% increase in U.S. sales. Earnings per share of $0.96 beat the consensus estimate of $0.6681, a $0.29 or 43% upside, while revenue exceeded the $278.3 million estimate by $38.7 million, a 14% beat.
The strong performance was underpinned by a combination of higher SUBLOCADE sales, disciplined cost control, and operational leverage. Adjusted EBITDA margin expanded to 52% from 29% in the prior year, reflecting favorable pricing, gross‑to‑net adjustments, and the impact of Phase I of the Indivior Action Agenda’s cost‑reduction initiatives, including headcount reductions and organizational restructuring. CEO Joe Ciaffoni said, "We are encouraged by our first quarter results, which reflect the progress we are making against Phase II of the Indivior Action Agenda – Accelerate. Year‑over‑year we accelerated SUBLOCADE net revenue and dispense unit growth and grew adjusted EBITDA and cash at an even faster rate while executing on our capital deployment strategy. We remain focused on accelerating SUBLOCADE dispense unit growth, growing our bottom line at a significantly faster rate, and strategically deploying capital as we earn our way to Phase III of the Indivior Action Agenda – Breakout – which we are on track to enter in the second half of 2026."
Capital activity in the quarter included the completion of a $500 million convertible senior notes offering, which was used to repay a $333 million term loan and support the company’s capital deployment strategy. The company also repurchased $125 million of shares during the quarter, leaving $275 million of a $400 million share‑repurchase program announced in February 2026. CFO Ryan Preblick noted, "Strong SUBLOCADE performance in the first quarter led us to raise our 2026 financial guidance. We now expect 2026 total SUBLOCADE net revenue growth of 13% year‑over‑year and adjusted EBITDA growth of 50% year‑over‑year at the midpoint of our guidance ranges. We strengthened our financial position with the completion of a $500 million convertible senior notes offering and returned capital to our shareholders through the opportunistic repurchase of $125 million in shares during the quarter. We are committed to creating long-term shareholder value as we advance the Indivior Action Agenda."
Indivior raised its full‑year 2026 guidance, now projecting total net revenue of $1.215 billion to $1.285 billion and adjusted EBITDA of $620 million to $660 million, up from the previous $1.15 billion to $1.25 billion and $580 million to $620 million range. The upward revision signals management’s confidence in sustained SUBLOCADE demand, the effectiveness of cost‑control measures, and the company’s ability to generate cash flow to fund future growth. The guidance also reflects the company’s expectation of entering Phase III of the Action Agenda in the second half of 2026, which will enable further strategic investments and potential acquisitions.
Indivior’s competitive position remains strong, with SUBLOCADE holding a 76% share of the U.S. long‑acting injectable opioid‑use‑disorder market and stable pricing for its other product, SUBOXONE Film. The company has decided not to pursue Phase III development for INDV‑6001 and has amended its license agreement with Alar Pharmaceuticals, focusing resources on its core product portfolio. These decisions, combined with the company’s robust cash position and debt reduction, position Indivory to capitalize on opportunities in the opioid‑use‑disorder treatment space while maintaining financial flexibility.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.